Organisation paid for research Program year 2025 Source: CMS Open Payments

Amarillo Heart Center LLC

Neither a doctor nor a teaching hospital

Research payments

$155,206

93 payments

Through program year 2025, Amarillo Heart Center LLC is reported as receiving $155,206 in research payments, across 93 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$96,825	87
2024	Research	$44,276	4
2023	Research	$14,106	2

Breakdown

Who paid Research payments · program years 2023–2025

Boehringer Ingelheim International GmbH $105,599 82 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $49,607 11 payments

Studies the money was for Research payments · program years 2023–2025

EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $68,440 68 payments
BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) $37,411 3 payments
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% $28,385 19 payments
Empagliflozin for prevention of HHF and death afte $14,106 2 payments
Empagliflozin for prevention of HHF and death after an AMI $6,865 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.